By Dr. Ankur Singh•11 August 2026

Stem Cell Therapy for Knee Arthritis: What the Evidence Actually Shows in 2026

A close-up shot of a man’s leg against a white background. He is holding his knee with both his hands.

If you have significant knee arthritis and have searched for alternatives to knee replacement surgery, you have almost certainly encountered stem cell therapy. The claims are persuasive: "regenerate cartilage," "avoid surgery permanently," "your own cells rebuilding your knee." Clinics across India — from Delhi's upmarket areas to Noida's medical hubs — advertise these treatments, often at prices ranging from ₹40,000 to ₹2 lakhs or more for a single injection.

An honest, evidence-based assessment of what these treatments can and cannot do is one of the most valuable things an orthopedic surgeon can offer patients considering them. This is that assessment.

The headline: regenerative biologics — PRP, SVF, and MSC therapies — are genuinely interesting treatments with meaningful evidence supporting their use in specific clinical situations. They are not the miracle cure that marketing materials suggest. Cartilage that has been lost does not grow back. But for the right patient at the right stage of disease, they offer real and evidence-supported symptom benefit.

The Three Main Types of Regenerative Injection Therapy

PRP — Platelet-Rich Plasma

What it is: Blood is drawn from the patient's arm, spun in a centrifuge to concentrate the platelets, and the platelet-rich layer is injected into the knee joint. Platelets are rich in growth factors — proteins that signal cell repair and regeneration. PRP is not strictly a "stem cell" therapy, but it is frequently grouped with regenerative treatments.

How it works (theoretically): The growth factors in PRP — PDGF, TGF-β, VEGF, IGF-1 — stimulate local repair processes, reduce inflammation in the synovial tissue, and may support chondrocyte (cartilage cell) activity. The anti-inflammatory effect may be the most clinically significant mechanism.

What the evidence shows: The evidence base for PRP in knee osteoarthritis is the most robust of any regenerative injection — with more than 20 randomised controlled trials. A 2021 Cochrane review and multiple meta-analyses consistently show that PRP reduces pain and improves function in knee osteoarthritis compared to placebo and compared to hyaluronic acid (another injection treatment), particularly in earlier-stage (Grade I and II) arthritis.

The benefit is real but not dramatic: most trials show a 20 to 40 percent reduction in pain scores at 6 to 12 months — meaningful for patients, but not the complete resolution some clinics suggest. PRP does not regenerate articular cartilage — MRI studies consistently show no change in cartilage thickness after PRP treatment. The benefit is symptom relief through reduced inflammation and improved joint environment.

Evidence rating: Moderate evidence for symptom benefit in early-to-moderate knee arthritis. Weak evidence in advanced (Grade III-IV, bone-on-bone) arthritis where less functional tissue remains to respond to growth factors.

Dr. Ankur Singh's practice: PRP injections for knee osteoarthritis are performed at KDSG Superspeciality Hospital and Renew Orthopedic Clinic for appropriately selected patients — primarily those with Grade I-II osteoarthritis who have not responded adequately to physiotherapy and NSAIDs, and for whom the goal is delaying more invasive intervention.

SVF — Stromal Vascular Fraction

What it is: Fat (adipose) tissue is liposuctioned from the patient's abdomen or thighs, processed to separate out the stromal vascular fraction — a mixture of cells that includes adipose-derived mesenchymal stem cells (ADMSCs), endothelial progenitor cells, pericytes, and immune cells. This cell mixture is then injected into the joint.

SVF is the treatment most commonly marketed in India under the label "stem cell therapy for arthritis" — because the SVF fraction does contain stem cells alongside other cell types.

What the evidence shows: SVF studies in knee arthritis are smaller and less robust than PRP trials, but emerging results are encouraging. Several prospective studies show pain reduction and functional improvement comparable to or better than PRP at 12 months, with some patients maintaining benefit at 24 months. No randomised controlled trial of SVF in knee arthritis has yet demonstrated cartilage regeneration on MRI — the benefit appears to be through the same anti-inflammatory and trophic mechanisms as PRP rather than true cartilage rebuilding.

The processing methodology significantly affects outcomes — the cell viability and composition of SVF varies considerably between preparation methods and clinics. An SVF product from a well-equipped clinical facility with standardised preparation is a different product from one prepared with minimal processing equipment.

Evidence rating: Emerging, promising evidence. Fewer high-quality trials than PRP. Requires robust preparation methodology to be clinically meaningful.

Regulatory note: SVF processing for re-injection is regulated in India under the New Drugs and Clinical Trials Rules (2019) and CDSCO guidelines. Clinics performing SVF injections should be operating under appropriate regulatory clearance — patients should ask about this.

MSC Therapy — Mesenchymal Stem Cells (Culture-Expanded)

What it is: Mesenchymal stem cells (from bone marrow, fat, or umbilical cord tissue) are extracted, grown (culture-expanded) in a laboratory over several weeks to produce millions of cells, and then injected into the joint. This is the most sophisticated — and most expensive — form of regenerative therapy. Culture-expanded MSC products can be autologous (from the patient's own tissue) or allogeneic (from donor tissue or umbilical cord).

What the evidence shows: MSC therapy for knee arthritis is the most scientifically plausible approach — MSCs have genuine multi-lineage differentiation capacity (they can theoretically become cartilage cells) and potent anti-inflammatory secretory activity (paracrine effects). Early clinical trials show significant pain reduction at 12 months, and some — using high cell doses — have shown modest improvements in cartilage thickness on MRI.

However, the evidence base remains limited. Most studies are small (20 to 100 patients), uncontrolled, and industry-funded. The optimal cell source, dose, delivery method, and patient selection criteria are not established. The promise of true cartilage regeneration remains more theoretical than clinical at this stage.

What is available in India: True culture-expanded MSC products require GMP (Good Manufacturing Practice) laboratory infrastructure. A small number of Indian facilities have this capability. Many clinics marketing "MSC therapy" are providing SVF or minimally processed bone marrow concentrate (BMAC) under this label — which is not the same product and should not be described with the same expectations.

Evidence rating: Scientifically promising, clinically early-stage. Evidence is accumulating but not yet sufficient for confident recommendations in standard clinical practice.

The Claims That Are Not Supported by Evidence

"We can regenerate your cartilage." No regenerative injection — PRP, SVF, or MSC — has been shown in high-quality trials to significantly regenerate articular cartilage in patients with established knee osteoarthritis. Individual cases and early exploratory trials have shown modest cartilage changes, but this is not a proven or reliable outcome.

"This will permanently cure your arthritis." Arthritis is a progressive disease. Regenerative injections — even the most promising — have shown benefit lasting 12 to 24 months in most studies. The underlying disease process continues. Most patients need repeat treatments.

"You will definitely avoid knee replacement." For early-stage arthritis where the joint has significant residual function, regenerative treatment may help delay the timeline significantly. For advanced bone-on-bone arthritis (Grade IV), regenerative therapies provide minimal benefit — there is insufficient viable tissue in the joint for growth factors to act on.

"Results in 2 to 4 weeks." Most regenerative therapies take 3 to 6 months to reach peak effect as the biological processes they stimulate take time to produce clinical change. Claims of dramatic improvement within weeks should be viewed sceptically.

Who Is the Right Candidate for Regenerative Therapy?

Based on the current evidence, patients most likely to benefit from regenerative injection therapy are:

Grade I to II knee osteoarthritis (mild to moderate cartilage loss, some joint space preserved on X-ray)
Younger patients (under 65) who want to delay joint replacement
Patients who have had partial or inadequate response to physiotherapy and corticosteroid injections
Patients without significant knee deformity (varus/valgus malalignment reduces the effectiveness of regenerative treatment by concentrating load on the treated area)
Patients with realistic expectations — who understand the goal is symptom management and disease modification, not cure

Patients who are least likely to benefit:

Grade III-IV bone-on-bone arthritis with severe joint space narrowing
Significant varus or valgus deformity (malalignment)
BMI above 35
Those who have already had multiple regenerative treatments without benefit

The Honest Conversation to Have Before Any Regenerative Treatment

Before paying for regenerative therapy in India, ask the clinic:

Which specific product are you injecting? PRP, SVF, bone marrow aspirate, or culture-expanded MSCs?
What is the evidence for this specific product in my grade of arthritis?
What regulatory clearances does your clinic have for this procedure?
What outcomes should I realistically expect, and over what timeframe?
If this does not work, what is the next step?

A clinic that answers these questions clearly and honestly is operating differently from one that offers only testimonials and promises.

Consultation at Dr. Ankur Singh's Practice in Noida

PRP injection therapy for appropriate patients is part of the management options available at Dr. Ankur Singh's practice. The decision to use regenerative therapy is made as part of a comprehensive treatment plan — with honest discussion of realistic outcomes, the stage of arthritis, and how regenerative therapy fits alongside or in place of other interventions.

To book a consultation at Renew Orthopedic Clinic, Sector 47 Noida, call the number listed on this website.

Frequently Asked Questions

Is PRP the same as stem cell therapy?

No. PRP does not contain stem cells — it is a concentrate of platelets and their growth factors. It is a regenerative therapy in the broad sense, but it is biologically distinct from SVF or MSC therapies that do contain stem cells. Marketing that describes PRP as stem cell therapy is misleading.

Why is there such a wide price range for these treatments in India?

The cost variation reflects differences in preparation method, cell processing technology, facility quality, and whether the product is a simple PRP concentration or a more sophisticated SVF or MSC preparation. A ₹15,000 PRP injection and a ₹1.5 lakh SVF procedure are not the same treatment.

Can regenerative therapy work alongside physiotherapy?

Yes — and the combination likely produces better outcomes than either alone. Regenerative injections reduce the inflammatory pain environment; physiotherapy builds the muscle support around the joint that protects it mechanically. They are complementary.

Medical Disclaimer

The information provided on this website is for educational purposes only and should not be considered as medical advice. Please consult Dr. Ankur Singh or a qualified healthcare professional for personalized medical guidance.